Literature DB >> 400941

Cefoxitin and cephamycins: microbiological studies.

E O Stapley1, J Birnbaum, A K Miller, H Wallick, D Hendlin, H B Woodruff.   

Abstract

The cephamycins are a family of beta-lactam antibiotics that are produced by actinomycetes and are structurally similar to the cephalosporins. They are characterized by the presence of a 7-alpha-methoxyl group, which confers unusually high resistance to beta-lactamases. Cefoxitin, the first semisynthetic cephamycin, is resistant to almost all beta-lactamases. Cefoxitin retains the 3-carbamoyl group of cephamycin C and thus has excellent metabolic stability. Cefoxitin is bactericidal and almost devoid of any inoculum effect. Active against many cephalothin-resistant gram-negative bacteria, cefoxitin demonstrates a very broad spectrum that includes indole-positive Proteus and many strains of Serratia. In contrast to that of the cephalosporins, cefoxitin's spectrum of activity against anaerobic pathogens includes Bacteroides fragilis. The therapeutic effectiveness of cefoxitin in experimental infections in mice confirms the excellent characteristics of this semisynthetic cephamycin and indicates that it should be a very valuable agent for treatment of bacterial infections.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 400941     DOI: 10.1093/clinids/1.1.73

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  16 in total

Review 1.  Discovery and development of new antimicrobial agents.

Authors:  T D Gootz
Journal:  Clin Microbiol Rev       Date:  1990-01       Impact factor: 26.132

Review 2.  The third generation cephalosporins.

Authors:  B Farber; R C Moellering
Journal:  Bull N Y Acad Med       Date:  1982-11

3.  Prophylactic regimens in colorectal surgery: comparisons between metronidazole used alone or with ampicillin for one or three days.

Authors:  M Roland; T Bergan; T Bjerkeset; H Erichsen; R Hoel; S Johansen; I Liavåg; S Reinertsen; A Rosseland; T Teigan
Journal:  World J Surg       Date:  1985-08       Impact factor: 3.352

4.  Newer antibiotics.

Authors:  A Kumar
Journal:  Indian J Pediatr       Date:  1981 Sep-Oct       Impact factor: 1.967

5.  Cephalosporins: recent developments.

Authors:  A Kumar
Journal:  J Natl Med Assoc       Date:  1983-02       Impact factor: 1.798

6.  Prediction and validation of enzyme and transporter off-targets for metformin.

Authors:  Sook Wah Yee; Lawrence Lin; Matthew Merski; Michael J Keiser; Aakash Gupta; Youcai Zhang; Huan-Chieh Chien; Brian K Shoichet; Kathleen M Giacomini
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-03       Impact factor: 2.745

7.  Clinical evaluation of cefotaxime for therapy of lower respiratory tract infections.

Authors:  C J Schleupner; J C Engle
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

8.  Alterations in human fecal flora, including ingrowth of Clostridium difficile, related to cefoxitin therapy.

Authors:  M E Mulligan; D Citron; E Gabay; B D Kirby; W L George; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

9.  Antibiotic prophylaxis with cefoxitin in colorectal surgery: effect on the colon microflora and septic complications--a clinical model for prediction of the benefit and risks in using a new antibiotic in prophylaxis.

Authors:  L Kager; I Ljungdahl; A S Malmborg; C E Nord; R Pieper; P Dahlgren
Journal:  Ann Surg       Date:  1981-03       Impact factor: 12.969

10.  Analysis of the Structure and Function of FOX-4 Cephamycinase.

Authors:  S T Lefurgy; V N Malashkevich; J T Aguilan; E Nieves; E C Mundorff; B Biju; M A Noel; R Toro; D Baiwir; K M Papp-Wallace; S C Almo; J-M Frere; G Bou; R A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2015-11-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.